Anti-CD33 CAR-NK92 cell therapy - PersonGen Biomedicine
Alternative Names: Anti-CD33 CAR-NK cells; Anti-CD33 CAR-NK92 cells; Anti-CD33 chimeric antigen receptor natural killer cell therapy - PersonGen Biomedicine; Anti-CD33 chimeric antigen receptor natural killer cells - PersonGen Biomedicine; Anti-CD33 chimeric antigen receptor natural killer92 cells - PersonGen Biomedicine; CAR-NK Cell immunotherapy - PersonGen BiomedicineLatest Information Update: 22 Feb 2022
At a glance
- Originator PersonGen Biomedicine
- Class Antineoplastics; CAR-NK cell therapies; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action CD33 antigen inhibitors; Gene transference; Natural killer cell receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 22 Feb 2022 No development reported - Phase-I/II for Acute myeloid leukaemia (In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in China (Parenteral)
- 01 Oct 2016 Phase-I/II clinical trials in Acute myeloid leukaemia (In adolescents, In adults, In children, In the elderly, Second-line therapy or greater) in China (Parenteral) (NCT02944162)